Biologics in Pediatric Rheumatology: Quo Vadis?

Yonit Sterba; Norman Ilowite

doi:10.1007/s11926-016-0593-9

Biologics in Pediatric Rheumatology: Quo Vadis?

Yonit Sterba, Norman Ilowite

Pediatrics

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

Original language	English (US)
Article number	45
Journal	Current Rheumatology Reports
Volume	18
Issue number	7
DOIs	https://doi.org/10.1007/s11926-016-0593-9
State	Published - Jul 1 2016

Keywords

Abatacept
IL-1 inhibitors
IL-6 inhibitors
Juvenile idiopathic arthritis (JIA)
Rituximab
TNF inhibitors
Tofacitinib

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1007/s11926-016-0593-9

Cite this

@article{8d267379a6b44d37bb30629a82793294,

title = "Biologics in Pediatric Rheumatology: Quo Vadis?",

abstract = "The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.",

keywords = "Abatacept, IL-1 inhibitors, IL-6 inhibitors, Juvenile idiopathic arthritis (JIA), Rituximab, TNF inhibitors, Tofacitinib",

author = "Yonit Sterba and Norman Ilowite",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = jul,

day = "1",

doi = "10.1007/s11926-016-0593-9",

language = "English (US)",

volume = "18",

journal = "Current Rheumatology Reports",

issn = "1523-3774",

publisher = "Current Science, Inc.",

number = "7",

}

TY - JOUR

T1 - Biologics in Pediatric Rheumatology

T2 - Quo Vadis?

AU - Sterba, Yonit

AU - Ilowite, Norman

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

AB - The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

KW - Abatacept

KW - IL-1 inhibitors

KW - IL-6 inhibitors

KW - Juvenile idiopathic arthritis (JIA)

KW - Rituximab

KW - TNF inhibitors

KW - Tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=84976508941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976508941&partnerID=8YFLogxK

U2 - 10.1007/s11926-016-0593-9

DO - 10.1007/s11926-016-0593-9

M3 - Review article

C2 - 27306623

AN - SCOPUS:84976508941

SN - 1523-3774

VL - 18

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

IS - 7

M1 - 45

ER -

Biologics in Pediatric Rheumatology: Quo Vadis?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this